New Hookworm Vaccine Could Have ‘Tremendous Impact’ On World’s Poorest

Huffington Post: A New Malnutrition Vaccine for the World’s Poor
Peter Hotez, founding dean of the National School of Tropical Medicine, and Remko van Leeuwen, director of acquisitions at the Amsterdam Institute of Global Health and Development (AIGHD) Foundation and coordinator of the HOOKVAC consortium

“…[A] report just released in the prestigious medical journal, Blood, reveals that anemia is now one of the most important causes of global illness, especially among women and children. … [A] neglected tropical disease (NTD) called hookworm is one of the leading causes of anemia. … The good news is that the Sabin Vaccine Institute’s Product Development Partnership (Sabin PDP) is developing the world’s first human hookworm vaccine, which could have a tremendous impact on the health, economic, and social landscape of countries with high burdens of this disease. … [This] human hookworm vaccine has been referred to as an ‘antipoverty vaccine’ because of its potential ability to improve child development, pregnancy outcome, and the health and productivity of agricultural workers. By conquering a leading cause of anemia in the developing world, the vaccine could become a truly important global health intervention…” (6/25).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.